文章摘要

CD90,Tenascin-C在甲状腺癌中的表达水平及临床病理学特征的关系

作者: 1,2刘 琬琳, 1,2文 铎, 1,2曹 一鸣, 1,2魏 文俊, 1,2朱 永学
1 复旦大学附属肿瘤医院头颈外科,上海 200032
2 复旦大学上海医学院肿瘤学系,上海 200032
通讯: 朱 永学 Email: jq_hai@126.com
DOI: 10.3978/j.issn.2095-6959.2019.09.004
基金: 国家自然科学基金(81772854);上海市自然科学基金(19ZR1410900)。

摘要

目的:研究CD90,Tenascin-C在甲状腺乳头状癌组织中的表达水平及其与临床病理特征的关系。方法:选取2016年1月至2018年12月复旦大学附属肿瘤医院病理科保存的甲状腺乳头状癌组织标本及对应癌旁组织70对,采用免疫组织化学和免疫荧光方法,检测癌与癌旁组织中CD90,Tenascin-C蛋白的表达情况并分析其与临床特征之间的关系。结果:癌组织CD90,Tenascin-C阳性表达率分别为60.30%和62.55%,高于癌旁组织的6.62%和6.87%(P<0.05)。CD90及Tenascin-C的表达与甲状腺乳头状癌患者的年龄、性别、肿瘤大小差异无统计学意义(P>0.05),但与有无淋巴结转移有关(P<0.05)。CD90+Tenascin-C双阳性与肿瘤多灶性,腺外侵犯及有无淋巴结转移有关(P<0.05),免疫荧光实验证实Tenascin-C蛋白与肿瘤相关成纤维细胞标志分子CD90的共存关系。结论:甲状腺乳头状癌组织中CD90,Tenascin-C呈高表达,与患者临床病理特征有一定关系。
关键词: CD90;Tenascin-C;肿瘤相关成纤维细胞;甲状腺乳头状癌;临床病理特征

Expressions of CD90 and Tenascin-C in thyroid papillary carcinoma and their relation with clinicopathological features

Authors: 1,2LIU Wanlin, 1,2WEN Duo, 1,2CAO Yiming, 1,2WEI Wenjun, 1,2ZHU Yongxue
1 Department of Head and Neck Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200030, China
2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200030, China

CorrespondingAuthor:ZHU Yongxue Email: jq_hai@126.com

Foundation: This work was supported by the National Natural Science Foundation (81772854) and Shanghai Natural Science Foundation (19ZR1410900), China.

Abstract

Objective: To study the expression levels of CD90 and Tenascin-C in papillary thyroid carcinoma and their relationship with clinicopathological features. Methods: A total of 70 cases of papillary thyroid carcinoma tissues were collected from the Department of Pathology of our hospital from Jan 2016 to December 2018. At the same time, 70 normal thyroid tissues were selected as controls. Immunohistochemistry and immunofluorescence were used to detect CD90 and Tenascin-C in cancer and adjacent tissues. The expression level of CD90 and Tenascin-C protein were analyzed with their relationship with clinical features. Results: The positive expression rates of CD90 and Tenascin-C in cancer tissues were 60.30% and 62.55%, respectively, which were higher than 6.62% and 6.87% in adjacent tissues, and the difference was statistically significant (P<0.05). The expressions of CD90, Tenascin-C were not significantly associated with age, gender, and tumor size in patients with papillary thyroid carcinoma (P>0.05), but were associated with lymph node metastasis (P<0.05). CD90 + Tenascin-C double positive was associated with tumor multifocal, extra-glandular invasion and lymph node metastasis (P<0.05). Immunofluorescence confirmed the coexistence of Tenascin-C protein and tumor-associated fibroblast marker CD90. Conclusion: CD90 and Tenascin-C were highly expressed in papillary thyroid carcinoma, which was related to the clinicopathological features of patients.
Keywords: CD90; tenascin-C; tumor-associated fibroblast; papillary thyroid carcinoma; clinicopathological features.